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Abstract: Background: Currently, used oral antiplatelet drugs are both limited and associated 
with the risk of treatment failure/resistance. Research in this area is hence highly desired. A series 
of xanthene-3-ones derivatives, we had synthesized, showed us that these derivatives had antiplate-
let activity. As far as we know, no research on the effects of xanthen-3-ones in this area has been 
done. 
Objective: The aim was to study the antiplatelet potential of a series of synthesised 9-phenyl-
xanthene-3-ones and to find the ideal structural feature(s) for antiplatelet potential and determine 
the mechanism of action. 
Methods: The compounds were synthesized from 1,2,4-triacetoxybenzene and various benzalde-
hydes. The reaction proceeded smoothly under acidic alcoholic conditions, furnishing the desired 
products in good yields. The compounds were first screened in whole human blood where platelet 
aggregation was induced by arachidonic acid. Further analysis was targeted at search of the 
mechanism of action. 
Results: Initial screening showed that a majority of the synthesized derivatives had substantial an-
tiplatelet potential. None of the compounds were able to block cyclooxygenase 1 or thromboxane 
synthase. The mechanism appeared to be based on antagonism of thromboxane effects. The most 
potent compound 9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one had better poten-
tial to block collagen induced platelet aggregation than clinically used acetylsalicylic acid. 
Conclusion: The last mentioned derivative is promising for further in vivo testing. 
Keywords: Platelet, xanthene-3-one, thromboxane, antiplatelet, cyclooxygenase, arachidonic acid. 
1. INTRODUCTION 
Finding, testing and describing the mechanism of action 
of new substances that block platelet aggregation is challeng-
ing. Current oral antiplatelet drugs include acetylsalicylic 
acid (ASA), an irreversible antagonist of cyclooxygenase-1 
(COX-1), and antagonists of ADP receptors P2Y12 (clopi-
dogrel, prasugrel, ticagrelor, elinogrel and cangrelor) Treat-  
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ment with both types of substances is problematic: in around 
5-45% of ASA users there is a treatment failure and/or resis-
tance [1] and antagonists to ADP receptors (ticlopidin and 
clopidogrel) are associated with drug interactions [2, 3]. The 
latest representatives of the latter (ticagrelor, elinogrel, can-
grelor) are not prodrugs and hence have a smaller potential 
for such interactions but their use in clinical practise is rela-
tively recent and the side-effects of long-term treatment have 
not yet been established. Consequently, discovery of new 
substances with antiplatelet potential on other aggregations 
levels is desired. Importantly, new drugs acting at different 
levels of aggregation than the targets of the currently used 
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oral anti-platelet drugs could overcome the complex issues 
with the drugs used.  
Platelet aggregation is a complex process which is still 
not fully understood. There are many proaggregatory stimuli. 
The key mediator appears to be thromboxane A2 (TXA2), 
which is synthetized in platelets on stimulation by various 
aggregation inducers including ADP, collagen and thrombin. 
TXA2 formation is initiated by release of arachidonic acid 
(AA) from the cytoplasmatic membrane, followed by its 
conversion by platelet COX-1 into prostaglandin H2 and into 
TXA2 via platelet thromboxane A2 synthase. Beyond proag-
gregatory activity, TXA2 is also a potent vasoconstrictor [4]. 
Moreover, platelet thromboxane A2 receptors are increased 
in patients with acute myocardial infarction [5]. 
Synthesis of xanthene-3-ones (9-Aryl-6-hydroxy-3H-
xanthen-3-one) as fluorescent sensors of divalent ions [6] and 
the antioxidant properties of another synthesized xanthene-3-
ones have been established [7], however up to now, the po-
tential use of xanthene-3-ones is limited. Two compounds, 9-
[1-(2-methyl-4-methoxyphenyl)]-6-hydroxy-3H-xanthen-3-
one (Tokyo green) and another fluorescein derivate 9-[1-(4-
tert-butyl-2-methoxyphenyl)]-6-hydroxy-3H-xanthen-3-one 
(Granada green) are sensitive dyes for intracellular phos-
phate detection [8, 9], 3’,6’-bis(4-guanidinobenzoyloxy)-5-
(N’-4-carboxylphenyl)thioureidospiro[isobenzofuran-1(3H), 
9’-[9H]xanthen]-3-one is useful for the detection of plasmi-
nogen activator activity [10] and 3’,6’-bis(diethylamino)-2-
(pyridine-2-ylmethyl)spiro[isoindoline-1,9’-xanthen]-3-one 
is highly efficient for the recognition and determination of 
Hg
2+
. [11] Research has also been targeted to xanthene-9-
ones. Two of these compounds showed anticancer proper-
ties. 1-hydroxy-3-(2´-hydroxy-3´-(butylamino)propoxy) xan-
thone acts as a topoisomerase II? inhibitor[12] and 4-[(2E)-
3,7-dimethoxyocta-2,6-dien-1yl]-1,5,8-trihydroxy-3-metho-
xy-9H-xanthen-9-one exhibited antiproliferative activity 
against leukemia cells [13]. Some xanthen-9-ones were 
found to be non-specific and highly active inhibitors of iso-
lated COX-1 and COX-2 enzymes [14]. As far as we know, 
no research on the effects of xanthen-3-ones toward platelets 
or COX enzymes has been conducted. 
A series of xanthene-3-ones derivatives was synthetized 
in an effort to find novel metal chelators. Interestingly, dur-
ing screening assays, we found that these derivatives had 
antiplatelet activity. This study was aimed to synthesize and 
investigate the antiaggregatory properties of newly synthe-
tized xanthene-3-one derivatives, to find ideal structural fea-
ture(s) for antiplatelet potential and to determine their 
mechanism of action. 
2. MATERIAL AND METHODS 
2.1. Chemistry 
2.1.1. Synthesis of Xanthene-3-on Derivatives 
Derivatives of xanthene-3-ones were prepared according 
to a known procedure which includes two-fold Friedel-Crafts 
alkylation of 1,2,4-triacetoxybenzene reflux in ethanol and 
sulphuric acid with addition of different benzaldehydes and 
potassium peroxodisulphate as an oxidizing agent. [15, 16] 
In detail, a round-bottom flask equipped with a condenser 
and mechanical stirrer was filled with 1,2,4-
triacetoxybenzene (5 g) and 50% EtOH (75 mL). Concen-
trated sulphuric acid (3 mL) was added and the white sus-
pension was heated to reflux, resulting in a clear, honey col-
ored solution. Various benzaldehydes (10 mmol) were added 
dropwise to the mixture over a 2 min period. The stirred 
mixture was kept at reflux for another 60 min. Potassium 
peroxodisulphate (2,70 g) was then gradually added at 80 °C 
over a period of 50 min. The contents were brought to reflux 
for another 20 min and then poured onto ice water. Obtained 
red crystals were washed with water and later dried in vac-
uum at 60 °C. 
2.1.2. General Methods. 
Microanalyses for C, H and N were performed on a 
Perkin Elmer 2400 elementary analyzer (Germany). The IR 
spectra of the synthesized compounds were recorded by 
Shimadzu IR Prestige 21 ID using KBr pellets. The 1H and 
13C nuclear magnetic resonance spectra were recorded at 
600 and 150 MHz, respectively, in deuterated dimethyl sul-
foxide (DMSO-d6) at 25 °C using the NMR spectrometer 
Bruker AV600, with tetramethylsilane as internal reference. 
Chemical shifts (?) are reported in ppm and coupling con-
stants (J) in Hz. Electrospray ionization mass spectrometry 
(ESI-MS) measurements were performed on a high perform-
ance liquid chromatography-mass spectrometry (HPLC-MS 
triple quadrupole 6420 instrument equipped with an auto-
sampler (Agilent Technologies, Palo Alto, CA, USA). The 
desolvation gas temperature was 300 °C with a flow rate of 
6.0 L min-1. The fragmentor voltage was 135 V and the cap-
illary voltage was 4.0 kV. The mobile phase was 0.1% for-
mic acid in 50% methanol and the flow rate of the mobile 
phase was 0.2 mL min-1. Mass spectra as total ion current 
spectra were recorded in m/z segment of 10-2250. All data 
acquisition and processing were performed using Agilent 
MassHunter software. The purity of the final compounds 
was ?99%.  
2.1.3. 9-(2'-hydroxy-5'-bromophenyl)-2,6,7-trihydroxy-
xanthene-3-one (1). 
Red crude material; yield 78.4%; m.p. 203 °C; IR (KBr) 
?max/cm-1: 3600-2500 (phenol OH); 750 (C-Br); 1650 
(C=O); 860 (substituted benzene); 1600 (C=O); 1300 (C-O); 
1200 (phenol OH); 
13
C NMR (150 MHz, DMSO-d6, ?/ppm): 
163.3 (C-12, C-13), 154.2 (C-6'), 152.5 (C-2, C-7), 147.6 (C-
3, C-6), 146.3 (C-9), 133.6 (C-4'), 132.4 (C-2'), 122.4 (C-1'), 
118.4 (C-5'), 116.0 (C-11, C-14), 110.3 (C-3'), 107.4 (C-1, 
C-8), 102.2 (C-4, C-5); 
1
H NMR (600 MHz, DMSO-d6, 
?/ppm): 10.19 (2H, br. s., OH), 9.90 (2H, br. s., OH), 7.63 
(1H, dd, H-4', J1 = 8.3 Hz, J2 = 2.0 Hz), 7.44 (1H, d, H-2', J 
= 2.8 Hz), 7.09 (1H, d, H-5', J = 9.1 Hz), 6.95 (2H, s, H-4, 
H-5), 6.55 (2H, s, H-1, H-8); ESI-MS (m/z): 417.1 (M+H)
+
; 
414.9 (M-H)
- 
Elemental analysis for C19H11O6Br (415.9): 
%Ccalculated. 54.82; %Hcalculated. 2.64: %Cfound: 54.86; %Hfound 
2.61; purity: 99.95%. 
2.1.4. 9-(2'-hydroxy-3'-methoxyphenyl)-2,6,7-trihydroxy-
xanthene-3-one (2) 
Cadmium red crude material; yield 86.7%; m.p. 178 °C; 
IR (KBr) ?max/cm-1: 3400-2400 (henol OH); 850 (substi-
tuted benzene); 1600 (C=O); 1300 (C-O); 1450 (O-CH3); 
13
C 
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NMR (150 MHz, DMSO-d6, ?/ppm): 163.0 (C-12, C-13), 
152.6 (C-2, C-7), 149.8 (C-9), 148.0 (C-5'), 147.5 (C-3, C-
6), 143.7 (C-6'), 121.6 (C-2'), 120.2 (C-1'), 119.5 (C-3'), 
116.2 (C-11, C-14), 112.8 (C-4'), 107.9 (C-1, C-8), 102.1 (C-
4, C-5), 55.9 (OCH3); 
1
H NMR (600 MHz, DMSO-d6, 
?/ppm): 9.91 (3H, br. s., OH), 9.13 (1H, br. s., OH), 7.23 
(1H, dd, H-4', J1 = 8.2 Hz, J2 = 1.5 Hz), 7.05 (1H, t, H-3', J = 
7.9 Hz), 7.00 (2H, s, H-4, H-5), 6.80 (1H, dd, H-2', J1 = 7.6 
Hz, J2 = 1.5 Hz ), 6.60 (2H, s, H-1, H-8), 3.92 (3H, s, 
OCH3). ESI-MS (m/z): 367 (M+H)
+ 
Elemental analysis for 
C20H14O7 (366): %Ccalculated. 65,60; %Hcalculated. 3.80: %Cfound: 
65.51; %Hfound 3.84; purity: 98.80%. 
2.1.5. 9-(3',4'-dihydroxyphenyl)-2,6,7-trihydroxy-xanthene-
3-one (3) 
Red crude material; yield 82.2%; m.p. 203-205 °C; IR 
(KBr) ?max/cm-1: 3600-2500 (phenol OH); 750 (C-Br); 
1650 (C=O); 860 (substituted benzene); 1600 (C=O); 1300 
(C-O); 1200 (phenol OH); 
13
C NMR (150 MHz, DMSO-d6, 
?/ppm): 152.4 (C-12, C-13), 151.9 (C-2, C-7), 147.5 (C-3, C-
6), 147.4 (C-9), 147.1 (C-4'), 145.5 (C-5'), 123.6 (C-1'), 
121.1 (C-2'), 116.9 (C-6'), 115.9 (C-3', C-11, C-14), 108.3 
(C-1, C-8), 102.1 (C-4, C-5); 
1
H NMR (600 MHz, DMSO-
d6, ?/ppm): 9.55 (5H, br. s., OH), 7.04 (1H, d, H-3', J = 8.1 
Hz), 7.01 (2H, s, H-4, H-5), 6.87 (1H, d, H-6', J = 2.1 Hz), 
6.86 (2H, s, H-1, H-8), 6.77 (1H, dd, H-2', J1 = 7.9 Hz, J2 = 
1.9 Hz); ESI-MS (m/z): 353.3 (M+H)
+ 
Elemental analysis for 
C19H12O7 (352): %Ccalculated. 64.80; %Hcalculated. 3.41: %Cfound: 
64.58; %Hfound 3.35; purity: 99.72% 
2.1.6. 9-(3',4'-dimethoxyphenyl)-2,6,7-trihydroxy-xanthe-
ne-3-one (4) 
Crude material; yield 68.5%; m.p. 168-169 °C; IR (KBr) 
?max/cm-1: 3400-2500 (phenol OH); 865 (substituted ben-
zene); 1600 (C=O); 1300 (C-O); 1200,1250 (phenol OH); 
1400 (O-CH3); 
13
C NMR (150 MHz, DMSO-d6, ?/ppm): 
152.0 (C-2, C-7), 149.5 (C-4'), 149.3 (C-5'), 147.4 (C-3, C-
6), 146.8 (C-9), 125.7 (C-1'), 121.9 (C-2'), 115.3 (C-11, C-
14), 113.0 (C-6'), 111.8 (C-3'), 107.0 (C-1, C-8), 102.2 (C-4, 
C-5), 55.8 (OCH3-5'), 55.6 (OCH3-4'). Signals of atoms C-12 
and C-13 were not detected; 
1
H NMR (600 MHz, DMSO-d6, 
?/ppm): 9.44 (2H, br. s., OH), 7.22 (1H, d, H-3', J = 8.1 Hz), 
7.04 (1H, d, H-6', J = 1.8 Hz), 6.97 (1H, dd, H-2', J1 = 8.1 
Hz, J2 = 1.8 Hz), 6.74 (2H, s, H-4, H-5), 6.55 (2H, s, H-1, H-
8), 3.89 (3H, s, OCH3-4'), 3.79 (3H, s, OCH3-5'); ESI-MS 
(m/z): 379.0 (M-H)
-
; 381.3 (M+H)
+ 
Elemental analysis for 
C21H16O7 (380): %Ccalculated. 66.32; %Hcalculated. 4.21: %Cfound: 
66.40; %Hfound 4.28; purity: 99.85%. 
2.1.7. 9-(3',5'-dimethoxy-4'-hydroxyphenyl)-2,6,7-trihydro-
xyxanthene-3-one (5) 
Crude material; yield 74%; m.p. 203 °C; IR (KBr) 
?max/cm?1: 3500-2500 (phenol OH); 1600 (C=O); 1300 (C-
O); 1200(def.vibr.OH); 1260 (O-CH3); 
13
C NMR (150 MHz, 
DMSO-d6, ?/ppm): 148.1 (C-3' and C-5'), 145.1 (C-9), 136.2 
(C-7, C-6), 123.2 (C-1'), 107.0 (C-1, C-8, C-2' i C-6'), 102.2 
(C-4 i C-5), 56.2 (OCH3); 
1
H NMR (600 MHz, DMSO-d6, 
?/ppm): 9.36 (2H, br. s., OH), 8.80 (1H, br. s., OH), 6.73 
(2H, s, H-4, H-5), 6.69 (4H, m, H-1, H-8, H-2' ,H-6' ), 3.71 
(6H, s, OCH3-3', OCH3-5'); ESI-MS (m/z): 397.4 (M+H)
+ 
Elemental analysis for C21H16O8 (396): %Ccalculated. 63.60; 
%Hcalculated. 4.04: %Cfound: 63.40; %Hfound 4.12; purity: 
99.72%.  
2.1.8. 9-(3'-methoxy-5'-nitro-4'-hydroxyphenyl)-2,6,7-trihy-
droxy-xanthene-3-one (6) 
Crude material; yield 79.2%; m.p. 214-217 °C; IR (KBr) 
?max/cm?1: 3700-2400 (phenol OH); 1600 (C=O); 1300 (C-
O); 1200 (def.vibr. OH); 1250 (O-CH3); 1380,1500 (NO2); 
13
C NMR (150 MHz, DMSO-d6, ?/ppm): 164.0 (C-12, C-
13), 152.5 (C-2, C-7), 149.8 (C-5'), 147.7 (C-3, C-6), 145.4 
(C-9), 142.8 (C-4'), 137.4 (C-3'), 123.6 (C-1'), 116.9 (C-6'), 
116.7 (C-2'), 115.6 (C-11, C-14), 107.0 (C-1, C-8), 102.3 (C-
4, C-5), 57.0 (OCH3). 
1
H NMR (600 MHz, DMSO-d6, 
?/ppm): 10.96 (2H, br. s., OH), 9.63 (2H, br. s., OH), 7.54 
(1H, d, H-2', J = 1.95 Hz), 7.39 (1H, d, H-6', J = 1.56 Hz), 
6.81 (2H, s, H-4, H-5), 6.56 (2H, s, H-1, H-8), 3.92 (3H, s, 
OCH3); ESI-MS (m/z): 412.3 (M+H)
+ 
Elemental analysis for 
C20H13O9N (411): %Ccalculated. 58.40; %Hcalculated. 3.16: 
%Cfound: 58.52; %Hfound 3.01; purity: 99.73%.  
2.1.9. 9-(4'-ethoxyphenyl)-2,6,7-trihydroxy-xanthene-3-one 
(7) 
Red crude material; yield 82.4%; m.p. 216 °C; IR (KBr) 
?max/cm-1: 3400-2500 (phenol OH); 3550 (OH); 800 (sub-
stituted benzene); 1600 (C=O); 1300 (C-O); 1200 (def.vibr. 
OH); 1270(ether R-O-C2H5); 
13
C NMR (150 MHz, DMSO-
d6, ?/ppm): 159.1 (C-4'), 152.0 (C-2 ,C-7), 147.4 (C-3, C-6), 
146.6 (C-9), 130.8 (C-2', C-6'), 125.3(C-1'), 115.3 (C-11, C-
14), 114.6 (C-3', C-5'), 106.9 (C-1, C-8),102.2 (C-4, C-5), 
63.3 (OCH2CH3), 14.6 (OCH2CH3); 
1
H NMR (600 MHz, 
DMSO-d6, ?/ppm): 9.43 (3H, br. s., OH), 7.36 (2H, d, H-2', 
H-6', J = 8.6 Hz), 7.19 (2H, d, H-3', H-5', J = 8.6 Hz), 6.73 
(2H, s, H-4, H-5), 6.50 (2H, s, H-1, H-8), 4.17 (2H, q, 
OCH2CH3, J = 6.9 Hz ), 1.41 (3H, t, OCH2CH3, J = 6.9 Hz); 
ESI-MS (m/z): 365.3 (M+H)
+ 
Elemental analysis for 
C21H16O6(364): %Ccalculated. 69.23; %Hcalculated. 4.40: %Cfound: 
69.12; %Hfound 4.26; purity: 99.75%. 
2.1.10. 9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xant-
hen-3-one (8) 
Crude material; yield 65.3%; m.p. 199-203 °C; IR (KBr) 
?max/cm?1: 3400-2400 (phenol OH); 834 (para-substituted 
benzene); 1500 (C=O); 1300 (C-O); 1200 (OH def.vibr); 
1440 (CH3-N); 1265 (C-N); 
13
C NMR (150 MHz, DMSO-d6, 
?/ppm): 160.9 (C-12, C-13), 158.0 (C-9), 152.8 (C-2, C-7), 
151.5 (C-4'), 147.3 (C-3, C-6), 131.6 (C-2', C-6'), 119.0 (C-
1'), 116.1 (C-11, C-14), 111.7 (C-3', C-5'), 109.6 (C-1, C-8), 
102.2 (C-4, C-5), 39.8 (NCH3); 
1
H NMR (600 MHz, DMSO-
d6, ?/ppm): 9.96 (1H, br. s., OH), 7.44 (2H, d, H-2', H-6', J = 
8.5 Hz), 7.23 (2H, s, H-4, H-5), 7.11 (2H, s, H-1, H-8), 7.03 
(2H, d, H-3', H-5', J = 8.9 Hz), 3.10 (6H, s, CH3); ESI-MS 
(m/z): 366.4 (M+H)
+ 
Elemental analysis for C21H17O5N 
(365): %Ccalculated. 69.40; %Hcalculated. 4.68: %Cfound: 69.61; 
%Hfound 4.46; purity: 99.50%. 
2.1.11. 9-(4'-trifluormethylphenyl)-2,6,7-trihydroxy-xan-
thene-3-one (9) 
Crude material; yield 69.4%; m.p. 212-214 °C; IR (KBr) 
?max/cm?1: 3400-2500 (phenol OH); 820 (para-substituted 
benzene); 1600 (C=O); 1300 (C-O); 1200 (def.vibr. OH); 
1030 (C-F); 
13
C NMR (150 MHz, DMSO-d6, ?/ppm): 151.6 
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(C-2, C-7), 147.8 (C-3, C-6), 144.2 (C-9), 138.2 (C-1'), 
130.3 (C-2', C-6'), 129.5 (C-4', q, JC,F = 31.8 Hz), 125.7 (C-
3', C-5', q, JC,F = 3.6 Hz), 124.1 (CF3, q, JC,F = 272.0 Hz ), 
115.0 (C-11 , C-14), 106.2 (C-1, C-8), 102.5 (C-4 , C-5). 
Signals of atoms C-12 and C-13 were not detected; 
1
H NMR 
(600 MHz, DMSO-d6, ?/ppm): 9.51 (2H, br. s., OH), 8.03 
(2H, d, H-3', H-5', J = 8.3 Hz), 7.71 (2H, d, H-2', H-6', J = 
8.3 Hz), 6.75 (2H, s, H-4, H-5), 6.31 (2H, s, H-1,H-8); ESI-
MS (m/z): 389.3 (M+H)
+ 
Elemental analysis for C20H11O5F3 
(388): %Ccalculated. 61.86; %Hcalculated. 2.83: %Cfound: 61.91; 
%Hfound 2.64; purity: 99.76%. 
2.1.2. 9-(4'-acetamidophenyl)-2,6,7-trihydroxy-xanthene-3-
one (10) 
Crude material; yield 81.6%; m.p. 209 °C; IR (KBr) 
?max/cm-1: 3400-2500 (phenol OH); 800 (para-substituted 
benzene); 1600 (C=O); 1300 (C-O); 1200,1250 (def.vibr. 
OH); 1420 (COO
-
); 1450-1500 (C-N, NH2 def.vibr); 
13
C 
NMR (150 MHz, DMSO-d6, ?/ppm): 160.9 (C-12, C-13), 
157.0 (C-9), 152.9 (C-2, C-7), 148.7 (C-4'), 147.4 (C-3, C-
6), 132.0 (C-2', C-6'), 121.0 (C-1'), 116.1 (C-11,C-14),115.2 
(C-3',C-5'),109.6 (C-1, C-8), 102.3(C-4,C-5); 
1
H NMR (600 
MHz, DMSO-d6, ?/ppm): 10.40 (2H, br. s., OH), 7.36 (2H, 
d, H-2',H-6', J = 8.5 Hz), 7.22 (2H, s, H-4, H-5), 7.08 (2H, s, 
H-1, H-8), 7.02 (2H, d, H-3', H-5', J = 8.3 Hz); Elemental 
analysis for C20H13O7N (379): %Ccalculated. 63.32; %Hcalculated. 
3.43: %Cfound: 63.41; %Hfound 3.25; purity: 99.73%. 
2.1.13. 9-(3'-bromophenyl)-2,6,7-trihydroxy-xanthene-3-
one (11) 
Crude material; yield 78.86%; m.p. 176-179 °C; IR 
(KBr) ?max/cm?1: 3400-2500 (phenol OH); 800 (meta-
substituted benzene); 1600 (C=O); 1300 (C-O); 1200,1230 
(phenol OH); 750 (C-Br); 
13
C NMR (150 MHz, DMSO-d6, 
?/ppm): 163.2 (C-12, C-13), 152.4 (C-2, C-7), 149.2 (C-9), 
147.7 (C-3, C-6), 135.6 (C-5'), 132.4 (C-4'), 131.5 (C-6'), 
131.0 (C-3'), 128.3 (C-2'), 122.1 (C-1'), 115.7 (C-11, C-14), 
107.2 (C-1, C-8), 102.3 (C-4, C-5); 
1
H NMR (600 MHz, 
DMSO-d6, ?/ppm): 7.88 (1H, d, H-4', J = 7.5 Hz), 7.75 (1H, 
t, H-6', J = 1.6 Hz), 7.65 (1H, t, H-3', J = 7.7 Hz), 7.51 (1H, 
dd, H-2', J1 = 8.2 Hz, J2 = 0.9 Hz), 6.97 (2H, s, H-4, H-5), 
6.52 (2H, s, H-1, H-8). Signals of OH groups were not de-
tected. ESI-MS (m/z): 401.3 (M+H)
+ 
Elemental analysis for 
C19H11O5Br (400): %Ccalculated. 57.00; %Hcalculated. 2.75: 
%Cfound: 57.31; %Hfound 2.84; purity: 99.60%.  
2.1.14. 9-(2'-chloro-6'-fluorophenyl)-2,6,7-trihydroxy-
xanthene-3-one (12) 
Crude material; yield 88.5%; m.p. 186-188 °C; IR (KBr) 
?max/cm?1: 3400-2500 (phenol OH); 860 (substituted ben-
zene); 1600 (C=O); 1300 (C-O); 1200(def.vibr. OH); 800(C-
Cl); 1100(C-F); 
13
C NMR (150 MHz, DMSO-d6, ?/ppm): 
164.0 (C-12, C-13), 159.3 (C-2', d, JC,F = 242.3 Hz), 151.7 
(C-2, C-7), 148.3 (C-3, C-6), 136.1 (C-9), 133.5 (C-6', d, JC,F 
= 3.9 Hz), 132.7 (C-4', d, JC,F = 9.3 Hz), 126.2 (C-5'), 120.5 
(C-1', d, JC,F = 21.2 Hz), 115.4 (C-11, C-14), 115.3 (C-3', d, 
JC,F = 22.6 Hz), 105.3 (C-1, C-8), 102.7 (C-4, C-5); 
1
H NMR 
(600 MHz, DMSO-d6, ?/ppm): 9.60 (2H, br. s., OH), 8.81 
(1H, br. s., OH), 7.76 (1H, d, H-4', J = 8.2 Hz), 7.69 (1H, t, 
H-5', J = 8.7 Hz), 7.58 (1H, td, H-3', J1 = 8.3 Hz, J2 = 6.1 
Hz), 6.75 (2H, s, H-4,H-5), 6.22 (2H, s, H-1, H-8); ESI-MS 
(m/z): 373.3 (M+H)
+ 
Elemental analysis for C19H10O5FCl 
(372.5): %Ccalculated. 61.21; %Hcalculated. 2.68; %Cfound: 61.35; 
%Hfound 2.72; purity: 99.82%.  
2.2. Biological activity 
2.2.1. Screening of the Antiplatelet Activity Induced by AA 
Aggregometer Multiplate (Roche, Switzerland) was used 
for screening of the antiplatelet activity. This device has two 
pairs of electrodes submerged in stirred human blood sam-
ples to measure the impedance between them. [17] 300 ?L of 
the whole blood was diluted by equipotent volume of pre-
heated 0.9% sodium chloride and incubated with 5 ?L of a 
tested compound dissolved in DMSO for 3 min at 37 °C. 
Platelet aggregation was then induced by addition of AA and 
the aggregation process was observed for 6 min and ex-
pressed as area under the curve. Since there is inherent vari-
ability in the general human population, the dose of AA was 
gradually increased in order to construct dose-response 
curves and to find the lowest dose to evoke maximal platelet 
aggregation. In screening experiments, 2 donors with compa-
rable response to AA (113 and 117 ?M) were used and other 
head-to-head experiments were always performed with the 
same donor to control for variance between individuals. 
ASA and kaempferol were used as standards to ensure the 
reproducibility of the results. All samples were compared to 
blank which contained 5 μL of DMSO instead of the tested 
compound. The concentration of DMSO was maintained in 
all samples at 0.8% (V/V). 
2.2.2. Cyclooxygenase-1 Inhibition 
A commercial set [18]
 
which does not give false positive 
results for antioxidants, was used for the evaluation of COX-
1 inhibition. Shortly, ASA or xanthene-3-ones dissolved in 
DMSO were incubated with ovine COX-1 at 37°C and AA 
(final concentration of 100 ?M) was added to the mixture to 
start the reaction. The formed prostaglandin H2 was meas-
ured following its reduction to prostaglandin F2? by stannous 
chloride and assessed by enzyme immunoassay. The per-
centage of inhibition was related to the positive control with 
DMSO. In additional experiments, PRP with a platelet con-
centration of 3,5 x10
8 
per mL, pre-treated with 1-
benzylimidazole, to block further metabolism of prostaglan-
din H2, was used instead of ovine COX-1 for testing the in-
hibition of human COX-1. The results were compared to 
ASA, the clinically used COX blocker. 
2.2.3. Thromboxane A2 Synthase Inhibition 
Thromboxane A2 synthase inhibition was evaluated ac-
cording to the method of Chang, et al [19] with minor modi-
fications. PRP containing indomethacin with a platelet con-
centration of 3.5 x10
8
 per mL was incubated with the tested 
compounds for 3 min at 37 °C. After addition of prostaglan-
din H2 (50 ng), the mixture was incubated for 5 min. The 
incubation was immediately terminated by addition of 
chilled EDTA (2 mM) and the solution was centrifuged at 
10,500 g for 2 min (centrifuge MPW-52, MPW Med. In-
struments). The thromboxane B2 levels in the supernatant 
were measured using a thromboxane B2 EIA kit according to 
the instructions of the manufactures. [20] Results were com-
pared to 1-benzylimidazol, a known blocker of thromboxane 
A2 synthase. 
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2.2.4. Antagonism at the Thromboxane Receptors 
Antagonism at thromboxane A2 receptors was analysed 
using of the aggregometer Multiplate. The procedure was 
similar to the screening but the aggregation was induced by 
the addition of U-46619, a stable agonist of thromboxane A2 
receptors. The aggregation process was monitored for 6 min. 
2.2.5. Aggregation Induced by Collagen 
The approach was very similar to antiplatelet screening 
with AA. The only exception was that collagen was used 
instead of AA. 
2.2.6. Statistical Analysis 
Data are presented as means ± SD. The differences be-
tween compounds were assessed by one-way ANOVA fol-
lowed by Tukey multiple comparison test. The differences 
between concentration-response curves were analysed using 
the 95% confidence intervals. All statistical evaluation was 
carried out using GraphPad Prism, version 6.00 (GraphPad 
Software, San Diego, USA). 
2.2.7. Blood Volunteers 
Blood samples from 11 non-smoking volunteers were 
collected by venipuncture into plastic disposable syringes 
containing heparin sodium (170 IU/10 mL). For specific 
experiments, the COX inhibitor indomethacin, or the throm-
boxane synthase inhibitor 1-benzylimidazole, were immedi-
ately added to the collected blood to a final concentration of 
10 ?M. The volunteers had not taken any medication for 
least 14 days before the blood collection and gave written 
informed consent to the study which was done with the ap-
proval of the Ethics Committee of Charles University in Pra-
gue, Faculty of Pharmacy in Hradec Králové (approval date: 
November 12, 2012) and conforms to the latest Declaration 
of Helsinki. Whole blood was used in screening experiments. 
In other experiments, platelet rich plasma was obtained as a 
supernatant by centrifugation of the collected blood for 10 
min at 500 g (centrifuge MPW-360, MPV Med. Instruments, 
Poland). Platelet poor plasma was prepared by centrifugation 
of the remaining blood for 10 min at 2,500 g. The platelet 
count was determined using a BD AccuriC6 flow cytometer 
(BD AccuriCytometers Inc., USA) equipped with BD CF 
low Software and adjusted to 2.5 or 3.5 x10
8 
platelets/mL 
according to the planned protocol (see above) using autolo-
gous plasma. 
3. RESULTS AND DISCUSSION 
3.1. Chemistry 
Twelve xanthen-3-one derivatives (1-12, Fig. 1) were 
prepared from 1,2,4-triacetoxybenzene and different aro-
matic aldehydes under acidic alcoholic conditions. After a 
two-fold Friedel-Crafts alkylation intermediate A was ob-
tained. For accomplishing the transformation, a single trihy-
droxy benzene moiety of A had to be oxidized using potas-
sium peroxodisulphate to the corresponding p-benzoquinone. 
To avoid decomposition of potassium peroxodisulphate, the 
reaction of oxidation occurred at 80°C. Benzoquinone inter-
mediate (B) subsequently underwent a cyclocondensation 
reaction to the xanthenone fragment. To remove potassium 
peroxodisulphate after completed oxidation, refluxed sus-
pension was poured onto ice water and filtered. The residue 
was dried under vacuum at 60 °C. The synthetic pathway (1-
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Fig. (1). Synthesis of xanthene-3-on derivatives. 
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12), adapted from [7] is shown in Fig. (1). The IR spectra of 
three new synthesized compounds showed absorption at 
2400-3600 cm
-1
 indicating phenyl OH groups. Xanthen-3-
one derivative with a methoxy group at aryl substituent (4-6) 
showed bands at 1250 cm
-1
 due to stretching vibrations of O-
CH3. The bands at 1500 cm
-1
 were visible on the spectra of 
the derivative with nitro group (6) due to stretching vibra-
tions of C–NO2. The compound with ethoxy group (7) 
showed absorption at 1270 cm
-1
 due to stretching vibrations 
of R-O-C2H5. On the IR spectra of compound 11 with bro-
mine at aryl substituent were visible bands at 750 cm
-1
 due to 
stretching vibrations of C-Br, while compound with fluor (9, 
12) showed bands at 1030-1100 cm
-1
 due to stretching vibra-
tions of C-F. The IR spectra of new synthesized compounds 
showed absorption frequencies around 1660 cm
-1
 and 1200 
cm
-1
 due to stretching vibrations of C=O and phenyl groups, 
respectively. On 
1
H NMR spectra two singlet signals be-
tween 6.22 and 6.97 ppm corresponded to 4 protons from the 
xanthen-3-one ring. Compounds with metha substituted 
phenyl ring by methoxy group (2, 5, 6) on 
1
H NMR revealed 
signals at 3.92 or 3.71ppm. 
1
H NMR of compound 7 with an 
ethoxy group substituted on the phenyl ring revealed quartet 
at 4.17 ppm and triplet at 1.41 ppm. Compound 8 with a di-
methylamino group on the phenyl ring on 
1
H NMR showed 
singlet at 3.10 ppm. Compound 10 with acetamido group 
substituted on the phenyl ring at the para positions on 
1
H 
NMR showed a doublet signal at 7.02 ppm. Characteristic 
signals of xanthen-3-one ring as well as all signals of sub-
stituent were found in 
13
C NMR spectra of all synthesized 
compounds. Compounds with methoxy substituent (2,5,6) on 
13
C NMR spectra showed signals at 55.9, 56.2 or 57 ppm 
associated with carbon atom from methoxy group. 
13
C NMR 
spectra of ethoxy substituted derivative 7 revealed signals at 
63.3 and 14.6 ppm. Compound 8 with dimethylamino group 
showed a signal at 39.8 ppm, while compound 9 with a 
trifluormethyl group substituted on the phenyl ring revealed 
a signal at 124.1 ppm. The results of the elemental analysis 
and mass spectroscopy indicate that the xanthen-3-one 
derivatives with described substitutions were synthesized. 
3.2. Biology 
3.2.1. Screening of the Antiplatelet Activity Induced by AA 
At first, all the compounds were separately incubated in 
whole human blood to investigate any possible antiplatelet 
activity. Blood was induced to aggregate by the addition of 
arachidonic acid. ASA, the standard antiplatelet drug, was 
used for comparison. Almost all compounds evoked signifi-
cant platelet inhibition at the highest tested concentration of 
80 ?M (Fig. 2A). Additional testing with different concentra-
tions led to the selection of two active compounds 9-(2'-
hydroxy-5-bromophenyl)-2,6,7-trihydroxy-xanthen-3-one 
(1) and 9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xan-
then-3-one (8) for further analysis. Their concentration-
response curves and at that for ASA were constructed at two 
different concentrations of AA in the blood of one donor to 
eliminate the interindividual variability (Fig. 2 B,C). Com-
pound 1 was a potent inhibitor of AA-induced aggregation 
but with significantly less effect than ASA (p<0.05). In con-
trast to ASA, compound 1 behaved in a competitive manner, 
since higher concentration of AA resulted in a decrease in 
antiplatelet potential (IC50 = 54.1 ± 1.3?M; 78.2 ± 1,1?M 
respectively). Compound 8 had a weaker effect independent 
of AA concentration used. 
3.2.2. Cyclooxygenase-1 Inhibition 
COX-1 inhibition was investigated as the first step in the 
AA based pathway to predict the mechanism of action of the 
selected active compounds. Compound 1 achieved higher 
COX-1 inhibition than ASA, whereas 8 demonstrated no 
effect in the test with recombinant ovine enzyme (p<0.05, 
Fig. 3A). To confirm the effect in human conditions, addi-
 
Fig. (2). Effect of compounds on whole human blood platelet ag-
gregation induced by AA. A: Comparison of the effects of all tested 
compounds (a final concentration of 80 ?M) on platelet aggregation 
(data from 2 blood donors, the precise final concentration of AA 
was 115 ± 2 ?M). Concentration-response curves of two active 
compounds at a final concentration of 123 ?M of AA (B) and 172 
?M (C) for one donor. Data are presented as means ± SD. * p < 
0.05; ** p < 0.01; *** p < 0.001 vs ASA; + p < 0.05; ++ p < 0.01; 
+++ p < 0.001 vs. solvent (DMSO). 
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tional testing was carried out on human platelet rich plasma 
(PRP). Here, ASA, the standard antiplatelet drug, showed 
excellent effect in units of ?M (IC50 = 23.0 ±1,1 ?M), while 
compound 1 showed no inhibition of COX-1 in human plate-
lets in concentrations below 50 ?M suggesting that this 
mechanism is likely unimportant for antiplatelet effects ob-
served in full human blood (Fig. 3B). 
2.2.3. TXA2 Inhibition 
The second step of the AA cascade is the transformation 
of prostaglandin H2 to TXA2 by thromboxane A2 synthase. 
None of the selected xanthene-3-ones inhibited TXA2 pro-
duction significantly at the highest tested concentration of 
100 ?M and are thus are considered inactive toward this en-
zyme (Fig. 4). 
2.2.4. Antagonism at Thromboxane Receptors 
Since the effect of both tested compounds on the synthe-
sis of both prostaglandin H2 and thromboxane A2 was negli-
gible, they should have an effect upstroke in the aggregation 
cascade. Hence, their effect on aggregation induced by U 
46619, a stable agonist at thromboxane receptors, was exam-
ined. Indeed, both compounds showed antagonism which 
was markedly more expressed in the case of compound 8 
(p<0.05, Fig. 5).  
 
Fig. (4). Effect of active tested compounds and 1-benzylimidazole 
on thromboxane A2 synthase. Compounds were tested at a concen-
tration of 100 ?M. 1-benzylimidazole at a concentration of 25 ?M 
(BI 25) is displayed for comparison. Data are presented as means ± 
SD. *p < 0.01 vs 1-benzylimidazole. Grey area refers to the error of 
the method. 
2.2.5. Aggregation Induced by Addition of Collagen 
For confirmation of the antiplatelet properties of the two 
active compounds, collagen as a more physiological ex-
 
Fig. (3). Effect of tested compounds on cyclooxygenase-1. A: Concentration-response curves of active compound 1, 8 and ASA on inhibition 
of recombinant ovine COX-1 and inhibition of human platelet COX-1 in human plasma (B). 
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tracellular inducer of platelet aggregation in whole blood 
was selected. The effect of compound 8 was not inferior to 
that of ASA, moreover this xanthene had effect in lower 
concentration than ASA, but due to the distinct curves their 
IC50 were comparable (51,5 ± 1,3 ?M vs. 50,5 ± 3,2 ?M). 
Compound 1 was clearly less active (Fig. 6). 
2.3. Discussion 
9-aryl-2,6,7-trihydroxy-xanthen-3-one derivatives were 
synthesized from 1,2,4-triacetoxybenzene and different sub-
stituted aromatic aldehydes using potassium peroxydisul-
phate as oxidant. Best reaction conditions were obtained 
when the oxidant was added dropwise over a range of about 
50 minutes. Additional reflux completed the conversion of 
benzoquinone intermediate and provided strongly coloured 
xanthen-3-one derivatives. Using analytical methods (ele-
mental analyses, IR, NMR, MS) the composition and struc-
ture of the synthesized compounds were confirmed. 
On the basis of the measured data, the structure-activity 
relationship in the group of new 9-fenylderivatives of xan-
thene-3-one was assessed. The most active compound block-
ing the aggregation induced by addition of AA was com-
pound 1, which has 2'-hydroxy-5'-bromophenyl group at-
tached to the common 9-phenyl-2,6,7-trihydroxy-xanthen-3-
one core. In general, the presence of a hydroxyl group in 
position 2´ or 3´ appears to be advantageous since beyond 
compound 1, compounds 2 and 3 were also among the most 
active derivatives. Alkyloxy groups in position 4´ markedly 
reduced the effect. In particular, compound 4 with 3´,4´-
dimethoxy group was inactive while compound 7 with a 4´-
ethoxygroup showed weak activity. In contrast, a methoxy 
group in position 3´ influenced the activity only slightly (e.g. 
difference among compounds 3-5). Different halogen substi-
tutions, with the possible exception of bromide in position 5´ 
of compound 1, had only minor effect on the activity. Direct 
comparison of the substituent at position 4´ showed the fol-
lowing order of activity: dimethylamine > trifluormethyl > 
acetamide > ethoxyl. 
The differences in AA assay among compounds 2, 3 and 
8 were very small. We selected compound 8 for further test-
ing because it retained its effect at lower concentration (data 
not shown). This was a particularly “lucky” selection since 
compound 8 (4´-dimethylamino derivative) was surprisingly 
more active on collagen-induced aggregation (Fig. 6) than 
compound 1 while the latter was the most potent inhibitor of 
AA-induced aggregation (Fig. 1). The collagen pathway is 
more complex and the clinically used acetylsalicylic acid is 
more potent inhibitor of AA pathway than collagen induced 
aggregation [21]. Since the collagen induced pathway is as-
sociated with TxA2, it is not surprising that a drug antagoniz-
 
Fig. (5). Effect of compounds at thromboxane receptors. The concentrations-response curves of tested compounds on platelet aggregation 
induced by U-46619. Data are presented as means ± SD. 
 
Fig. (6). Effect of compounds on whole blood platelet aggregation induced by collagen. Concentration-response curves of the two most ac-
tive compounds. Data are presented as means ± SD. 
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ing the effect of TxA2 would also block collagen-induced 
aggregation. Why compound 1 was a more potent inhibitor 
of platelet activation caused by AA than compound 8 even if 
the latter seemed to be a more potent antagonist at throm-
boxane receptors, is not clear. We cannot rule out the idea 
that compound 8 might possess an effect on the collagen 
pathway which was not discovered in this study. In any 
event, from a clinical viewpoint, a potent effect on collagen 
triggered platelet aggregation is more important since exoge-
nous administration of AA is rather artificial in contrast to 
collagen. In sum, compound 8 had a comparable or even 
better effect than clinically used acetylsalicylic acid and a 
different mechanism of action. Since antiplatelet treatment is 
aimed at inhibition of platelet aggregation in among others, 
patients with coronary artery disease [22] and thromboxane 
A2 receptors are upregulated in acute myocardial infarction 
[5], a (novel) compound acting as an antagonist at these 
thromboxane receptors could be a potentially interesting 
drug. 
We also showed that compound 1 had very good effect in 
blocking recombinant ovine COX-1, but this effect was not 
seen in human plasma suggesting it is not important for the 
final effect of this compound. Some xanthene-9-ones acted 
as potent inhibitors of ovine cyclooxygenase 1, but due to 
marked structural differences, no direct conclusion can be 
drawn [14]. Interestingly, compound 8 did not block ovine 
COX-1 and no significant activity of our active compounds 
on thromboxane synthase was observed. 
Our results suggest that future testing should be aimed in 
two directions: 1) in vivo confirmation of the antiplatelet 
potential of compound 8 associated with analysis of pharma-
cokinetics and 2) modification of compounds 1 and 8 to find 
the most active substitution pattern.  
CONCLUSION 
In summary, this study refers to a series of novel synthe-
sized compounds with potent antiplatelet activity. The anti-
platelet activity was based on antagonism of thromboxane A2 
effect. The most active compound 9-(4'-dimethylamino-
phenyl)-2,6,7-trihydroxy-xanthene-3-one is worthy of further 
in vivo testing of both a pharmacokinetic and pharmacody-
namics, character. 
LIST OF ABBREVIATIONS 
AA = arachidonic acid 
ASA = acetylsalicylic acid 
COX-1 = cyclooxigenase-1 
EDTA = ethylendiamintetraacetic acid 
ESI-MS = Electrospray ionization mass spec-
trometry 
PRP = platelet rich plasma 
PPP = platelet poor plasma 
TXA2 = thromboxane A2 
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